StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, FY2020
182
Period ended Dec 31, 2020
Change on a year earlier
-36.1%
285 in FY2019
History
5 years
Since FY2016
Sources
5
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)Year on yearSource
FY2020Dec 31, 2020182-36.1%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
FY2019Dec 31, 2019285-42.7%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
FY2018Dec 31, 2018497-33.8%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2017Dec 31, 2017751-34.2%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2016Dec 31, 20161,141–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Breakdown

What makes up vytorin (ezetimibe/simvastatin, legacy pre-organon spin-off) — worldwide sales ($m)

Cite this data

StockData. (2026). Merck Vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M), annual FY2016–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_vytorin

See every metric in the Merck KPI table. Data updated Oct 26, 2026.